Location: New York, NY
CIK: 0001633313 · Show all filings
Period: Q4 2022 (← Previous) (Next →)
Filing Date: Feb 14, 2023
Total Value: $6.692B (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| UTHR | UNITED THERAPEUTICS CORP | 2,865,000 | $797M | 11.9% | $133.73 | +88.8% | Common | 91307C102 |
| — | HORIZON THERAPEUTICS PLC | 7,000,000 | $797M | 11.9% | $66.26 | — | Common | G46188101 |
| APLS | APELLIS PHARMACEUTICALS INC | 10,625,000 | $549M | 8.2% | $48.29 | +9.8% | Common | 03753U106 |
| MDGL | MADRIGAL PHARMACEUTICALS INC | 1,660,000 | $482M | 7.2% | $118.73 | -17.6% | Common | 558868105 |
| ARGX | ARGENX SE | 1,265,555 | $479M | 7.2% | $136.82 | — | Sponsored ADR | 04016X101 |
| SRPT | SAREPTA THERAPEUTICS INC | 3,175,000 | $411M | 6.1% | $97.25 | +19.2% | Common | 803607100 |
| ASND | ASCENDIS PHARMA | 3,100,000 | $379M | 5.7% | $124.43 | — | Sponsored ADR | 04351P101 |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 3,555,555 | $368M | 5.5% | $83.64 | +12.2% | Common | 09061G101 |
| FOLD | AMICUS THERAPEUTICS INC | 26,800,000 | $327M | 4.9% | $10.43 | +7.9% | Common | 03152W109 |
| ALNY | ALNYLAM PHARMACEUTICALS INC | 1,105,000 | $263M | 3.9% | $153.75 | +38.7% | Common | 02043Q107 |
| — | MIRATI THERAPEUTICS INC | 5,555,555 | $252M | 3.8% | $53.82 | — | Common | 60468T105 |
| — | SEAGEN INC | 1,885,000 | $242M | 3.6% | $146.25 | — | Common | 81181C104 |
| XENE | XENON PHARMACEUTICALS INC | 4,900,000 | $193M | 2.9% | $16.29 | +123.5% | Common | 98420N105 |
| — | IVERIC BIO INC | 6,750,000 | $145M | 2.2% | $8.28 | — | Common | 46583P102 |
| KRYS | KRYSTAL BIOTECH INC | 1,410,000 | $112M | 1.7% | $63.51 | +16.9% | Common | 501147102 |
| BCRX | BIOCRYST PHARMACEUTICALS INC | 9,050,000 | $104M | 1.6% | $12.22 | +2.0% | Common | 09058V103 |
| KYMR | KYMERA THERAPEUTICS INC | 3,850,000 | $96.1M | 1.4% | $31.77 | -16.1% | Common | 501575104 |
| — | DICE THERAPEUTICS INC | 2,525,555 | $78.8M | 1.2% | $29.10 | — | Common | 23345J104 |
| SNDX | SYNDAX PHARMACEUTICALS INC | 2,650,000 | $67.44M | 1.0% | $21.05 | +10.8% | Common | 87164F105 |
| — | CYMABAY THERAPEUTICS INC | 10,300,000 | $64.58M | 1.0% | $6.26 | — | Common | 23257D103 |
| MNKD | MANNKIND CORP | 9,100,000 | $47.96M | 0.7% | $3.56 | +15.1% | Common | 56400P706 |
| NUVL | NUVALENT INC | 1,555,555 | $46.32M | 0.7% | $28.65 | -2.6% | Common | 670703107 |
| RNAM | AVIDITY BIOSCIENCES INC | 2,050,000 | $45.49M | 0.7% | $21.36 | -30.2% | Common | 05370A108 |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | 7,020,000 | $44.86M | 0.7% | $16.40 | -52.4% | Common | 462260100 |
| — | MERSANA THERAPEUTICS INC | 7,550,000 | $44.24M | 0.7% | $21.34 | — | Common | 59045L106 |
| KURA | KURA ONCOLOGY INC | 3,105,000 | $38.53M | 0.6% | $23.38 | -37.8% | Common | 50127T109 |
| WHWK | AADI BIOSCIENCES INC | 2,849,402 | $36.56M | 0.5% | $24.27 | -46.2% | Common | 00032Q104 |
| RARE | ULTRAGENYX PHARMACEUTICAL INC | 750,000 | $34.75M | 0.5% | $64.00 | -38.5% | Common | 90400D108 |
| GLUE | MONTE ROSA THERAPEUTICS INC | 4,325,000 | $32.91M | 0.5% | $17.56 | -52.6% | Common | 61225M102 |
| PMVP | PMV PHARMACEUTICALS INC | 3,060,000 | $26.62M | 0.4% | $25.09 | -57.5% | Common | 69353Y103 |
| DSGN | DESIGN THERAPEUTICS INC | 2,272,222 | $23.31M | 0.3% | $25.64 | -47.2% | Common | 25056L103 |
| AMLX | AMYLYX PHARMACEUTICALS INC | 630,000 | $23.28M | 0.3% | $24.95 | +42.2% | Common | 03237H101 |
| — | MARINUS PHARMACEUTICALS INC | 3,150,000 | $12.54M | 0.2% | $12.20 | — | Common | 56854Q200 |
| TNGX | TANGO THERAPEUTICS INC | 1,640,000 | $11.89M | 0.2% | $11.71 | -40.0% | Common | 87583X109 |
| FENC | FENNEC PHARMACEUTICALS INC | 1,200,000 | $11.52M | 0.2% | $9.85 | -10.2% | Common | 31447P100 |
| IOBT | IO BIOTECH INC | 2,055,883 | $4.729M | 0.1% | $9.66 | -72.6% | Common | 449778109 |